Automated Blood Collection Robot Aletta Receives FDA Approval for Market Launch, Blood Collection Success Rate Comparable to Manual
FDA approves automated blood collection robot Aletta for market launch. The device utilizes near-infrared light and Doppler ultrasound to locate veins, achieving full automation of the blood collection process, allowing one phlebotomist to monitor three devices simultaneously.
The FDA has approved the automated blood collection robot Aletta for market launch. The device can independently complete the full outpatient venous blood collection process. It integrates functions such as vein localization, tourniquet application, needle insertion, and waste disposal, aiming to improve medical operational efficiency.
Aletta's core technology lies in its vein localization system, which identifies patient arm veins through near-infrared light and Doppler ultrasound technology. This multi-sensor fusion solution is a typical application of artificial intelligence in the fields of medical imaging and perception, effectively addressing localization challenges under complex vascular conditions.
The deployment of this device will significantly optimize the manpower allocation of the blood collection process. One professional phlebotomist can monitor up to three Aletta robots simultaneously, which directly alleviates the industry pain point of the continuously expanding shortage of professional phlebotomists and improves the service throughput of medical institutions.
Aletta's approval marks the further implementation of AI and robotics technology in the field of medical assistance. The application of such automated devices not only helps standardize medical operation processes but also provides a new technical path for solving the problem of tight medical resources.
This page provides an editorial summary based on publicly available information. It is not a republished article. Use the source link below for the original report.